Overview

Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare two medications currently injected intra-operatively to help decrease pain after surgery in patients undergoing a primary total hip replacement (THR). The two medications are Exparel® (bupivacaine liposome injectable suspension) plus bupivacaine with epinephrine versus bupivacaine with epinephrine. This study is looking to see if one medication works better than the other in managing post-operative pain after THR. The study hypothesis is that Exparel® plus bupivacaine with epinephrine will demonstrate better pain management in THR patients post-operatively. Both medications are FDA-approved for post-operative analgesia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
American Hip Institute
Treatments:
Bupivacaine
Epinephrine
Epinephryl borate
Racepinephrine
Criteria
Inclusion Criteria:

- Patients scheduled to undergo primary unilateral total hip replacement

- Patients diagnosed with hip osteoarthritis

- Patients failed to improve with conservative measures

- Patients willing and able to sign informed consent

Exclusion Criteria:

- Revision total hip replacement

- Bilateral total hip replacement

- Birmingham hip resurfacing

- Patients with hepatic/kidney disease

- Patients with a known allergy to bupivacaine or other local anesthetics